secwatch.observer — SEC 8-K summary
======================================

Issuer:     Olema Pharmaceuticals, Inc. (OLMA)
CIK:        0001750284
Form:       8-K
Filed at:   2023-10-10T23:59:59+00:00
Accession:  0001558370-23-016301
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Olema and Novartis expand Phase 1/2 combo study of palazestrant + ribociclib to ~60 patients
--------------------------------------------------------------------------------

- Amendment adds ~30 patients to dose expansion, increasing study size to about 60 total.
- Phase 1b dose escalation completed; Phase 2 expansion at 120 mg palazestrant + 600 mg ribociclib.
- Expanded dataset may support regulatory path for a first-line pivotal trial in ER+ breast cancer.
- Collaboration originally signed July 2020; amended in January 2022 and now expanded again.
- Olema (OLMA) and Novartis (NVS) partner on this combination trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750284/000155837023016301/0001558370-23-016301-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750284/000155837023016301/olma-20231009x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-016301

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer